Scope of the Report
The report titled “Global Botulinum Toxin Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global botulinum toxin market with detailed analysis of the actual and the expected market size along with the market size of each market segment on the basis of indication as well as products.
The report provides detailed regional analysis of the U.S., European Union, Japan and Korea for the botulinum toxin market. Regional analysis includes market share of each region or country and the actual and forecasted market size of the botulinum toxin market along with the market segments of the aforementioned regions.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global botulinum toxin market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global botulinum toxin market is stiff and dominated by the big players like Allergan. Further, key players of the botulinum toxin market Ipsen and Revance are also profiled with their financial information and respective business strategies.
Regional Coverage
- The U.S.
- European Union
- Japan
- Korea
Company Coverage
- Allergan PLC.
- Ipsen
- Revance Therapeutics, Inc.
Executive Summary
Botulinum toxin is produced by clostridium botulinum, a gram-positive anaerobic bacterium. It is broken into seven neurotoxins. Currently, it is used in almost every sub-specialty of medicine and for cosmetic purpose for temporarily reducing glabeller forehead frown lines. The various botulinum toxins possess individual potencies, and care is required to assure proper use and avoid medication errors.
The global botulinum toxin market has increased at a significant annual growth rate in 2015 as compared to the preceding year 2014 and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The upsurge in the market was due to various factors such as increased patient comfort, shorter procedure times and immediate results. The market can be segmented on the basis of indications as therapeutics and aesthetics, of which therapeutics govern the market.
The major growth drivers for the botulinum toxin market are: upsurge in the facial aesthetics market, reduction in prices of botulinum toxin treatment and social awareness among people. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as side-effects of consuming botulinum toxin and bioterrorism.
Tags :
1. Executive Summary
2. Introduction
2.1 Sub-Types of Botulinum Toxin
2.2 Indications for Botulinum Toxin
2.3 Botulinum Toxin Products
3. Global Botulinum Toxin Market: An Analysis
3.1 Global Botulinum Toxin Market by Value: Actual and Forecast
3.2 Global Botulinum Toxin Market by Indication Segments
3.2.1 Global Therapeutic Botulinum Toxin Market by Value: Actual and Forecast
3.2.2 Global Therapeutic Botulinum Toxin Market by Indications
3.2.3 Global Aesthic Botulinum Toxin Market by Value: Actual and Forecast
3.2.4 Global Aesthetic Botulinum Toxin Market by Number of Cases
3.3 Global Botulinum Toxin Market by Product Segments
3.3.1 Global Botox Market by Value: Actual and Forecast
3.3.2 Global Dysport Market by Value: Actual and Forecast
3.3.3 Global Xeomin Market by Value: Actual and Forecast
3.3.4 Global Myobloc Market by Value: Actual and Forecast
3.4 Global Botulinum Toxin Market by Regions
4. Regional Botulinum Toxin Market: An Analysis
4.1 The U.S. Botulinum Toxin Market: Sizing and Growth
4.1.1 The U.S. Botulinum Toxin Market by Value: Actual and Forecast
4.1.2 The U.S. Botulinum Toxin Market by Indication Segments: Actual and Forecast
4.1.3 The U.S. Aesthetic Botulinum Toxin Market by Number of Cases
4.2 European Union Botulinum Toxin Market: Sizing and Growth
4.2.1 European Union Botulinum Toxin Market by Value: Actual and Forecast
4.2.2 European Union Botulinum Toxin Market by Indication Segments: Actual and Forecast
4.3 Japan Botulinum Toxin Market: Sizing and Growth
4.3.1 Japan Botulinum Toxin Market by Value: Actual and Forecast
4.3.2 Japan Botulinum Toxin Market by Indication Segments: Actual and Forecast
4.3.3 Japan Aesthetic Botulinum Toxin Market by Number of Cases
4.4 Korea Botulinum Toxin Market: Sizing and Growth
4.4.1 Korea Botulinum Toxin Market by Value: Actual and Forecast
4.4.2 South Korea Aesthetic Botulinum Toxin Market by Number of Cases
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Facial Aesthetic Market
5.1.2 Reducing Price Trend
5.1.3 Social Awareness
5.2 Challenges
5.2.1 Side-Effects of Botulinum Toxin for Consumers
5.2.2 Bioterrorism
5.3 Market Trends
5.3.1 RT001 and RT002
6. Competitive Landscape
6.1 Global Botulinum Toxin Companies Product Comparison
6.2 Korea Botulinum Toxin Companies Product Comparison
7. Company Profile
7.1 Allergan PLC.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Ipsen
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Revance Therapeutics, Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
Figure 1: Botulinum Toxin Products
Figure 2: Global Botulinum Toxin Market by Value; 2013-2015 (US$ Billion)
Figure 3: Global Botulinum Toxin Market by Value; 2016E-2020E (US$ Billion)
Figure 4: Global Botulinum Toxin Market by Indication Segments; 2015 (%)
Figure 5: Global Therapeutic Botulinum Toxin Market by Value; 2013-2020E (US$ Billion)
Figure 6: Global Therapeutic Botulinum Toxin Market by Indication; 2015 (%)
Figure 7: Global Aesthetic Botulinum Toxin Market by Value; 2013-2020E (US$ Billion)
Figure 8: Global Aesthetic Botulinum Toxin Market by Number of Cases; 2010-2014 (Million)
Figure 9: Global Botulinum Toxin Market by Product Segments; 2015 (%)
Figure 10: Global Botox Market by Value; 2013-2020E (US$ Billion)
Figure 11: Global Dysport Market by Value; 2013-2020E (US$ Million)
Figure 12: Global Xeomin Market by Value; 2013-2020E (US$ Million)
Figure 13: Global Myobloc Market by Value; 2013-2020E (US$ Million)
Figure 14: Global Botulinum Toxin Market by Regions; 2015 (%)
Figure 15: The U.S. Botulinum Toxin Market by Value; 2013-2015 (US$ Billion)
Figure 16: The U.S. Botulinum Toxin Market by Value; 2016E-2020E (US$ Billion)
Figure 17: The U.S. Botulinum Toxin Market by Indication Segments; 2013-2020E (US$ Billion)
Figure 18: The U.S. Aesthetic Botulinum Toxin Market by Number of Cases; 2010-2014 (Million)
Figure 19: European Union Botulinum Toxin Market by Value; 2013-2015 (US$ Billion)
Figure 20: European Union Botulinum Toxin Market by Value; 2016E-2020E (US$ Billion)
Figure 21: European Union Botulinum Toxin Market by Indication Segments; 2013-2020E (US$ Million)
Figure 22: Japan Botulinum Toxin Market by Value; 2013-2015 (US$ Million)
Figure 23: Japan Botulinum Toxin Market by Value; 2016E-2020E (US$ Million)
Figure 24: Japan Botulinum Toxin Market by Indication Segments; 2013-2020E (US$ Million)
Figure 25: Japan Aesthetic Botulinum Toxin Market by Number of Cases; 2010-2014 (Thousand)
Figure 26: Korea Botulinum Toxin Market by Value; 2013-2015 (US$ Million)
Figure 27: Korea Botulinum Toxin Market by Value; 2016E-2020E (U$ Million)
Figure 28: South Korea Aesthetic Botulinum Toxin Market by Number of Cases; 2010-2014 (Thousand)
Figure 29: Global Botulinum Toxin Market for Facial Aesthetic Treatment; 2011-2016E (US$ Billion)
Figure 30: The U.S. Average Medical Expenditure for Aesthetic Botulinum Toxin Procedures; 2010-2014 (US$)
Figure 31: Global RT001/RT002 Market; 2019E-2025E (US$ Million)
Figure 32: Global Botulinum Toxin Market by Players; 2015 (%)
Figure 33: Allergan PLC. Total Revenues; 2011-2015 (US$ Billion)
Figure 34: Allergan PLC. Revenues by Segments; 2015 (%)
Figure 35: Allergan PLC. Revenues by Products
Figure 36: Ipsen Total Revenues; 2011-2015 (US$ Billion)
Figure 37: Ipsen Revenues by Segments; 2015 (%)
Figure 38: Ipsen Sales by Regions; 2015 (%)
Figure 39: Revance Therapeutics, Inc. Total Revenues; 2011-2015 (US$ Thousand)
Figure 40: Revance Therapeutics Inc., Research and Development Expenditure; 2011-2015 (US$ Million)
Table 1: Applicable Indications of Botulinum Toxin
Table 2: Staus of Global Botulinum Toxin Companies
Table 3: Status of Korean Botulinum Toxin Companies
Table 4: Allergan PLC. Products yet to be Launched
